Dr. Randy Sweis
Hematology & Oncology (Hematology & Oncology Physician)
5841 S Maryland Ave
Chicago, IL 60637
Who else practices at this address →
Cook County includes primary care (3% of residents) and mental health (4% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of Chicago, Pritzker School of Medicine (2010)
- Years since graduation
- 16
- In the NPI registry since
- 2010
- Medicare patients seen, 2024
- 101
Licensed in Illinois since 2013, according to the Illinois Department of Financial and Professional Regulation. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2010Medical school: University of Chicago, Pritzker School of Medicine
- 2010Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
IL license 036132765 (first issued 2013; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- The University of Chicago Medical Center Chicago, IL
- Doctors Hospital Columbus, OH
- Uchicago Medicine Northwest Indiana Crown Point, IN
Medical groups
- Ohiohealth Corporation (2,314 clinicians)
- University of Chicago (1,712 clinicians)
- The University of Chicago Medical Center (915 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 101
- Services billed
- 329
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 133 | 59 |
| Established patient office or other outpatient visit, 30-39 minutes | 72 | 51 |
| New patient office or other outpatient visit, 60-74 minutes | 16 | 16 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisone Other prescribers in Chicago, IL | 78 |
| Abiraterone Acetate | 64 |
| Cabometyx (cabozantinib s-malate) | 39 |
| Lenvima (lenvatinib mesylate) | 18 |
| Orgovyx (relugolix) | 17 |
| Prochlorperazine Maleate Other prescribers in Chicago, IL | 15 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 4 companies reported 5 payments worth $5,037 in total to this clinician.
| Eisai Inc. | $2,564 |
|---|---|
| Eisai Co., LTD. | $2,355 |
| Eli Lilly and Company | $60.00 |
| Merck Sharp & Dohme LLC | $58.10 |
| Consulting Fee | $4,710 |
|---|---|
| Food and Beverage | $327 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Eisai Co., LTD. Mar 14, 2025 | Consulting Fee Lenvima · Oncology | $2,355 |
| Eisai Inc. May 5, 2025 | Consulting Fee Lenvima · Oncology | $2,355 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 10 industry-funded studies in 2025, from 7 companies. The companies reported $1,216,316 in research payments for these studies, mostly to the institutions running them.
- A Phase 1b,2 Study of Immune and Targeted Combination Therapies in Participants with RCC KEYMAKER-U03# substudy 03B in Second-Line Metastatic Participants
Merck Sharp & Dohme LLC - FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
Eli Lilly and Company · Recruiting · NCT05614739 - A Phase 1b,2 Study of Immune and Targeted Combination Therapies in Participants with RCC KEYMAKER-U03# Substudy 03A in First Line Metastatic Participants
Merck Sharp & Dohme LLC - A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
Regeneron Pharmaceuticals, Inc. · Recruiting · NCT06413680 - Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies
ModernaTX, Inc. · Completed · NCT03739931 - Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
ModernaTX, Inc. · Recruiting · NCT05533697 - A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors
Ascendis Pharma Endocrinology Inc · Terminated · NCT04799054 - Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/PD-L1 Based Immunotherapy
Gilead Sciences, Inc. - Phase II Dual-Cohort Study Evaluating the Effects of Pembrolizumab in the Presence of Gut Microbiota Modulation with EDP1503 in Advanced Melanoma Naïve or Refractory to Anti-PD1 Antibody
Merck Sharp & Dohme LLC - A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy alone versus Neoadjuvant Chemotherapy plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post-Surgery Therapy with Nivolumab or Nivolumab and BMS…
E.r. Squibb & Sons, L.l.c.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.